Summary. Sulodexide is a glycosaminoglycan extracted from porcine intestinal mucosa. The purpose of this review is to discuss sulodexide's complex pharmacological profile and its clinical applications for venous disease. Sulodexide has wide-ranging biological effects on the vascular system, including antithrombotic, profibrinolytic, anti-inflammatory, endothelial protective and vasoregulatory effects. Sulodexide has emerged as a potential therapeutic option for the management of chronic venous insufficiency, including venous ulceration, and the prevention of recurrent venous thromboembolism, with a low rate of major bleeding complications. Sulodexide's pleiotropic vascular effects may facilitate the management of common venous disorders.
Introduction
Sulodexide (Vessel; Alfasigma, Bologna, Italy) is a naturally occurring glycosaminoglycan that is purified from porcine intestinal mucosa. It is prescribed to help manage chronic venous disease (CVeD) and to prevent recurrent venous thromboembolism (VTE) in parts of Europe, South America, and Asia. However, it has not been approved by the US Food and Drug Administration. In this article, we review the pharmacological properties of sulodexide and the current evidence for its clinical applications, specifically for the treatment of CVeD and VTE.
Composition, molecular structure, and pharmacology
Sulodexide is a glycosaminoglycan, and consists of unbranched polysaccharide chains formed by the repetition of a specific disaccharide unit [1] . The molecular size of glycosaminoglycans can vary widely, and they can be composed of either sulfated (e.g. chondroitin sulfate, dermatan sulfate, keratan sulfate, heparin, and heparan sulfate) or non-sulfated (e.g. hyaluronic acid) monosaccharides [2] . Glycosaminoglycans have numerous critical functions, particularly the regulation of protein activity via cell signaling affecting chemokines, cytokines, growth factors, and adhesion molecules, along with antiproteolytic effects [3] .
The endothelial luminal surface is lined by the glycocalyx, which consists of a carbohydrate-rich layer of proteoglycans, hyaluronic acid, glycoproteins, and adsorbed plasma proteins. The glycocalyx has multiple roles, including control of vascular tone and response to shear stress, regulation of permeability, inhibition of complement activity, and interaction with leukocytes and platelets [1, 4] . For its function of maintaining favorable blood flow, the glycocalyx has an antithrombotic and profibrinolytic surface. Pivotal to this process is antithrombin, which is bound to heparan sulfate proteoglycans and interacts with coagulation factors to control the coagulation cascade [5] . Heparin, which is a sulfated glycosaminoglycan, chas multiple protective effects on the endothelium, including anti-inflammatory effects via protection against reactive oxygen species, inhibition of leukocyte binding, and downregulation of cytokines. Heparin also binds directly to the endothelium and reconstitutes the glycocalyx.
Sulodexide contains ⁓ 80% heparan sulfate (also known as fast-moving heparin) and 20% dermatan sulfate [6] . The heparan sulfate congener is predominantly composed of glucuronic acid linked to glucosamine (Fig. 1A) . The sulfated domains resemble those of heparin, and share its protein-binding properties, although heparan sulfate chains are generally longer than those of heparin [2] . Heparan sulfate has a molecular weight of 7000 Da, as compared with 4000-5000 Da for low molecular weight heparin and 15 000 Da for unfractionated heparin. There is less sulfation and anticoagulant activity with slow-moving heparin than with unfractionated heparin [7] . Heparan sulfate affects global coagulation to a lesser degree than unfractionated heparin or low molecular weight heparin, has a longer half-life, and has oral bioavailability [8] . It also possesses a high affinity for antithrombin [6, 9] .
Dermatan sulfate is composed of a disaccharide unit comprising iduronic acid and galactosamine (Fig. 1B) , with a mean molecular weight of 25 000 Da, and is mainly found in the vascular walls, skin, dermis, and heart valves [2]. It plays an important role in directing components of fibrillar collagen. Dermatan sulfate exerts anticoagulant activity by inhibition of factor X, and activates thrombin via heparin cofactor II, which is a natural inhibitor [10] . In a recent study by Veraldi et al., digestion of sulodexide by chondroitinase and heparinase enabled further characterization of the monosaccharide, disaccharide and oligosaccharide composition, which may lead to a better understanding of its makeup with regard to future therapeutic potential [6] .
Sulodexide is manufactured for use in intravenous and intramuscular forms, along with oral capsules. Peak concentrations are reached soon after intravenous injection, decrease over a period of 1-4 h, and then reach a null concentration after 18 h (Table 1) [7, 11] . Unlike other heparins, sulodexide can be absorbed intestinally. When taken orally, sulodexide has a median bioavailability of ⁓ 40% and a time to peak concentration of ⁓ 4 h [8, 11] . Sulodexide has a unique affinity for the surface of the endothelium rather than for plasma proteins. In rats, coagulation test results are abnormal after intravenous administration, but not after oral administration [12] . Parenterally administered sulodexide prolongs the activated partial thromboplastin time in a dose-dependent fashion. Metabolism occurs via the liver, and excretion is mostly renal [12] .
Biological mechanisms
Sulodexide's numerous biological effects contribute to its clinical applications, including reduction of venous and arterial thrombogenesis, anti-inflammatory effects, and endothelial protection (Fig. 2) .
Sulodexide's antithrombotic effects are central to its clinical applications via the antiprotease activities of both antithrombin and heparin cofactor II, with resultant inhibition of thrombin formation [13] . Owing to the dual composition of sulodexide, the two separate antithrombotic pathways are believed to work synergistically to decrease thrombin formation and create a greater antithrombotic effect than either component alone [13] . Sulodexide also accelerates spontaneous fibrinolysis of formed thrombi, with increased levels of tissue plasminogen activator and decreased plasminogen activator inhibitor, leading to a reduction in circulating fibrinogen [14, 15] . Sulodexide may also reduce platelet aggregation [16] .
Complementary to the direct effects on the coagulation system are the anti-inflammatory properties of sulodexide, which may also contribute to reducing thrombogenesis. Sulodexide inhibits leukocyte activation and adhesion to endothelial cells, and decreases the release of cytokines, tumor necrosis factor and platelet aggregation factor from polymorphonuclear leukocytes [2, 16] complement proteins, cytokines, and growth factors. Also, the release of cytokines, chemokines and adhesion molecules is decreased by binding of heparin to the positively charged nuclear localization sequence of nuclear factor-jB preventing its translocation into the nucleus [1, 17] . Heparins also inhibit adhesion to endothelial cells by binding to L-selectin and P-selectin [1, 17] . Additionally, in an evaluation of venous wound fluid, there was an increase in the level of soluble endoglin after exposure to sulodexide. Soluble endoglin affects leukocytes adhesion and transmigration through the endothelium. Sulodexide potentiates the effects of soluble endoglin release from monocytes, and this is hypothesized to be an important anti-inflammatory effect in venous ulceration [18] . Sulodexide suppresses the effects of macrophages by decreasing the secretion of inflammatory mediators, including interleukin-1b, interleukin-7, interleukin-8, interleukin-12, interleukin-17, and granulocyte colony-stimulating factor, from lipopolysaccharide-stimulated macrophages [19, 20] . In vivo, evaluation of venous ulcer fluid exposed to sulodexide demonstrated reduced release of interleukin-2, interleukin-12, interleukin-10, and vascular endothelial growth factor [21] . Cultured human umbilical endothelial cells showed decreased release of monocyte chemotactic protein-1 and interleukin-6, and decreased generation of intracellular free radicals, in a dose-dependent fashion when exposed to sulodexide [22] . It is believed that the heparan component suppresses the production of superoxide in neutrophils [22] . The generation of reactive oxide species is also decreased by upregulation of superoxide dismutase activity [23] .
Sulodexide also acts as a heparanase inhibitor, exclusively via the heparan component [24] . Heparanase cleaves heparin sulfate chains from heparin sulfate proteoglycans, which can damage the glycocalyx. Degradation of the glycocalyx allows for easier adhesion of inflammatory cells, lipid accumulation in the intima, and release of cytokines and chemokines bound to heparan sulfate proteoglycans [24, 25] . Additionally, heparanase activates macrophages via toll-like receptors [19] . Sulodexide also has numerous antiproteolytic effects via modulation of serine and metalloprotease enzymes, and matrix metalloproteinases (MMPs) [19, [26] [27] [28] [29] . MMPs are proteolytic enzymes that degrade the extracellular matrix and play a role in various detrimental vascular processes, including chronic venous insufficiency. In vivo, sulodexide downregulates the release of multiple MMPs from monocytes exposed to wound fluid from venous leg ulcers [29] . MMPs are also involved in shedding of the glycocalyx, leukocyte extravasation, and atherosclerotic plaque instability. Sulodexide is believed to affect modulate MMPs by various mechanisms, including direct interaction with MMPs, decreasing their synthesis, or interference with the signaling cascade that is activated by bacterial lipopolysaccharide [29] .
Central to sulodexide's vascular beneficial effects are protection and repair of the endothelium. The endothelium is essential for homeostasis of the coagulation system, by modulating the local inflammatory milieu and regulating vascular tone. It also plays an important role in recovery of the negative charge, which repels platelets, and preservation of the thickness of the glycocalyx via heparin binding. Paramount to the maintenance of endothelial integrity and function are glycosaminoglycans, which provide a structural matrix and cover the endothelial surface to assist in the regulation of permeability [2] . Sulodexide maintains and restores the functionality of the endothelial glycocalyx, possibly because of enhanced abundance of precursors of endothelial glycoaminoglycans [30] . In diabetic rats, sulodexide decreased the number of circulating endothelial cells and improved endothelium-dependent relaxation in small arteries [31] . Additional endothelial protective effects include sulodexide's potentiation of mitogenic activity, protection against denaturation and enzymatic degradation of fibroblast growth factor-1 and fibroblast growth factor-2, and modification of endothelial cell migration and proliferation [32] . Sulodexide also influences cholesterol catabolism. A previous study demonstrated lower levels of triglycerides and increased levels of HDL via the release of lipoprotein lipase [33] . In the same study, sulodexide decreased plasma viscosity.
Clinical applications
Most clinical applications of sulodexide are centered on CVeD and the prevention of recurrent VTE.
CVeD
CVeD represents the sequelae of venous insufficiency, which span a wide spectrum of clinical manifestations, from asymptomatic venous hypertension and varicose veins to the development of venous ulceration. The prevalence of CVeD may be as high as 73% in women and 56% in men [34] . CVeD decreases quality of life and increases the number of days off work, accounting for 1-2.5% of healthcare budgets in developed countries [35] .
The predominant pathophysiological mechanism of CVeD is the development of venous hypertension as a result of reflux from incompetent valves and/or venous obstruction [36, 37] . Venous hypertension can lead to venous dilatation, worsening valve insufficiency, and the generation of a perpetuating cycle of increasing pressure and further dilatation, which is initiated in the early stages of the disease. The changes in hemodynamics are transmitted to the microcirculation via biomechanical transduction signaling through the endothelium, with a resultant increased inflammatory and proteolytic microenvironment, and digestion of elastin in the vessel wall [38, 39] . Venous microangiopathy ensues, with dilatation and tortuosity of capillary beds, increased collagen deposition, endothelial damage, and widening of interendothelial spaces, leading to pericapillary edema [40] . This process activates an inflammatory cascade in the molecular microvascular network, including macrophages, endothelial cells, and an increase level of MMPs [26] . Increased infiltration of fibrinogen and other proteins form pericapillary fibrin cuffs, along with activation of leukocytes and platelets, results in the formation of microthrombi and impaired microcirculatory flow [41] .
Changes to the endothelium play an important role in the pathophysiology of CVeD. The endothelial glycocalyx translates biomechanical forces into protective biochemical signals, such as the production of nitric oxide [42] [43] [44] . The mechanical stress caused by luminal flow is transferred to the glycocalyx. Laminar shear stress can increase the production of factors that reduce the level of reactive free radicals and inflammation [45] . An intact glycocalyx also decreases leukocyte adhesion by concealing adhesion molecules. With the development of venous hypertension, there is a decrease in laminar flow and high shear stress, with resultant turbulent flow or even reversal of flow [41] . These changes in flow result in leukocyte adhesion, with degranulation of cytoplasmic granules and proteolytic enzyme release [41, 42, 46, 47] . Activated neutrophils and monocytes are sequestered within the local microenvironment, with additional activation of mast cells [18, 48] . Through these various mechanisms, there is a release of inflammatory mediators, including chemokines, cytokines, MMPs, VCAM-1, transforming growth factor-b, fibroblast growth factor-b, and vascular endothelial growth factor, that contribute to the inflammatory milieu. Such inflammation creates an environment that causes remodeling of the vein walls and valves, and venous dilatation. This further propagates venous hypertension, with the formation of varicosities and possible ulceration [49] [50] [51] .
Sulodexide has been evaluated in clinical trials of venous insufficiency. Cospite et al. evaluated changes in the microcirculation by measuring the coefficient of capillary filtration with serial strain gauge plethysmography in a double-blind, placebo-controlled trial of 36 patients with idiopathic varicose veins [52] . The group that received sulodexide showed a lower coefficient of capillary filtration at 30 days and 45 days of treatment than at baseline. A higher coefficient of capillary filtration reflects increased capillary permeability, which can result in greater interstitial fluid accumulation. Saviano et al. reported their findings in 476 patients with CVeD in a double-bind, double-dummy study. Half of the patients had CVeD secondary to post-thrombotic syndrome, and half had CVeD resulting from idiopathic varicose veins. Subjects were split into three groups, with an equal distribution of post-thrombotic syndrome and idiopathic varices in each group. Subjects received sulodexide 25 mg twice daily, 50 mg twice daily or 100 mg once daily for 60 consecutive days; a placebo group was not included [53] . Standing and supine venous pressure was measured with Doppler phlebotensiometry of the bilateral greater saphenous and posterior tibial veins at baseline and after 1 months and 2 months of treatment. At both 1-month and 2-month follow-up, venous pressures were lower in all groups. There was a dose-dependent response, with a greater decrease in venous pressure among those who received 100 mg daily. Mild to moderate gastrointestinal adverse effects occurred in 10% of patients, but resolved without intervention after 72 h, and did not require discontinuation of the therapy. Subsequently, an observational, single-arm, prospective study was performed evaluating the clinical efficacy of sulodexide in 450 patients with CVeD [42] . After 3 months of treatment, there were significant improvements in symptom and quality of life scores.
In patients with severe venous insufficiency, there can be progression to venous ulceration with an associated high degree of morbidity. Sulodexide interrupts multiple pathophysiological pathways that lead to CVeD, and thus has a potential adjunctive role in the management of venous ulceration. In addition to the antithrombotic, anti-inflammatory and hemodynamic effects of sulodexide, it upregulates the expression of hepatocyte and fibroblast growth factors, which promote vascular repair [54] . Furthermore, sulodexide inhibits growth factors with profibrotic and proangiogenic effects, such as vascular endothelial growth factor and transforming growth factor-b [54, 55] .
Four randomized trials have compared sulodexide with standard therapy in patients with venous ulceration (Table 2) [56] [57] [58] [59] . The Sulodexide Arterial Venous Italian Study (SUAVIS) group evaluated sulodexide in 235 patients with a venous ulceration of >2 cm in diameter in a double-blind, multicenter, randomized control trial. There were higher complete ulceration healing rates in the sulodexide group than in the placebo group at 2 months (35.0% versus 20.9%, P = 0.018) and at 3 months (52.5% versus 32.7%, P = 0.004) [57] . The time to healing of the ulcer was also lower in the sulodexide group. Adverse events occurred in 23 patients (19.1%) in the sulodexide group, four of which were considered to be treatment-related (one patient with rash, one with diarrhea, one with epigastric pain, and one with headache), with a rate similar to the overall rate in the placebo group (15.4%).
Sulodexide was also studied in patients with large venous ulcers (mean surface area of 12.4 cm 2 ), and there was a healing rate of 70% at 7 weeks in the sulodexide group as compared with 35% in the control group (P < 0.05) [58] . A systematic review of all four randomized trials found a number needed to treat of four for healing of venous ulcers [60] . Given the consistent findings of improved rates of healing with sulodexide, some guidelines recommend sulodexide as a pharmacological therapy for patients with venous ulceration, including the Society for Vascular Surgery and the American Venous Forum, and the American College of Chest Physicians [61, 62] .
There is no randomized trial assessing the role of sulodexide in the prevention or progression of CVeD. However, Luzzie et al. evaluated the presence of postthrombotic syndrome in a registry of 339 patients after completion of anticoagulation for deep vein thrombosis (DVT) [63] . Patients chose whichever treatment option they preferred: (i) standard management with compression, exercise, and risk factor reduction; (ii) sulodexide 25 mg twice daily plus standard therapy; or (iii) aspirin 100 mg daily plus standard therapy. The rate of postthrombotic syndrome was lower in those who took sulodexide than in those who opted for standard management at 60 months (12.2% vs. 19.5%, P < 0.05) and in those in the aspirin group (12.2% versus 23.5%, P < 0.05).
VTE
Sulodexide has affinity for the endothelium rather than for plasma proteins, and has little effect on systemic coagulation parameters. Therefore, it has been evaluated for the prevention of recurrent VTE, with the expectation that it might have a lower bleeding risk profile than alternative oral anticoagulation agents.
An early study of sulodexide's role in the prevention of recurrent VTE was performed by Errichi et al. in a registry of 405 patients with prior DVT who had received 6 months of anticoagulation [64] . Of those in the registry, 178 in the control group and 189 in the sulodexide group (oral capsules of 25 mg twice daily for 24 months) completed 6-month, 12-month, 18-month and 24-month lower-extremity venous ultrasound scans. The groups were similar in age, sex, and localization of thrombi at the time of inclusion. The rate of recurrent DVT was lower in those that who received sulodexide (7.4% versus 17.9%; P < 0.05). Soon after this, sulodexide was compared with the vitamin K antagonist acenocoumarol [65] . The study included 150 patients admitted with a proximal acute DVT. They received dose-adjusted nadroparin and 300 000 IU daily of urokinase for a total of 5 days, after which they were randomized to receive sulodexide 30 mg twice daily or acenocoumarol dose-adjusted for an International Normalized Ratio of 2-3 for a total of 3 months. There was no difference in recurrent VTE at 3 months, but there was a higher bleeding rate in the acenocoumarol group than in the sulodexide group (13% versus 0%; P = 0.014). The role of sulodexide in decreasing recurrent DVT was most robustly evaluated in the Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) study, a multicenter, randomized, double-blind, placebo-controlled trial that compared sulodexide 50 mg twice daily with placebo for 2 years, in addition to elastic stockings [66] . The study included 615 patients who had completed 3-12 months of oral anticoagulation after an initial unprovoked VTE. DVT had occurred in 92% of patients and pulmonary embolism in 8% as the index event in both groups. The primary efficacy outcome was recurrence of VTE, with a primary safety outcome of major or clinically relevant bleeding. Recurrent VTE occurred in 4.9% of patients in the sulodexide group and in 9.7% of patients in the placebo group (hazard ratio [HR] 0.49, 95% confidence interval [CI] 0.27-0.92; P = 0.02; adjusted HR 0.45, 95% CI 0.24-0.84; P = 0.01) (Fig. 3 ). There were no major bleeding events in either group; two patients in each group had clinically relevant non-major bleeding. There were also similar rates of adverse events in the two groups.
There is a biological rationale for sulodexide's efficacy in both CVeD and VTE. There is an overlap in the pathophysiology of the two processes. Inflammation is vital in the development of the clinical sequelae of more severe forms of CVeD. There is also a growing appreciation of the contribution of inflammation to the development of VTE [67] . Furthermore, disruption of the integrity of the endothelium can also be important in the development of both VTE and CVeD. Finally, both processes represent a prothrombotic state -although it is more obvious in the setting of VTE, the reduction in shear stress seen in CVeD leads to the release of prothrombotic agents, which may be mitigated by sulodexide [41] .
Conclusion
Sulodexide has both anti-inflammatory and antithrombotic effects, with modulation of cytokines, chemokines, and growth factors, along with proteinases and degrading enzymes. There are data supporting sulodexide's clinical benefit for patients throughout the spectrum of CVeD, from varicose veins to ulceration, and reduction of recurrent VTE. Appreciation of sulodexide's effects on inflammation, thrombosis, and proteolysis, and protection and reconstruction of the endothelium, emphasizes the fundamental role that the endothelium has in vascular disease [68, 69] . Sulodexide is a unique pharmacological agent with two components that result in a wide array of beneficial vascular effects. Its complex biological properties support the plausibility of its clinical applications. Sulodexide may be a useful treatment option for patients with CVeD and prior VTE. 
